Commentary

Article

State of the Science Summit: Lung Cancer — Chaired by: Muhammad Furqan, MD

In Partnership With:

State of the Science Summit: Lung Cancer — Chaired by: Muhammad Furqan, MD

State of the Science Summit: Lung Cancer — Chaired by: Muhammad Furqan, MD

Speakers

  • Muhammad Furqan, MD
  • Margaret Byrne MD, MSc
  • Bharat Jenigiri, MD

Topics

  • Perioperative Strategies in NSCLC
  • Targeting ALK NSCLC
  • Treatment of EGFR NSCLC

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
T. Jeroen N. Hiltermann, MD, of University of Groningen
Benjamin Besse, MD, PhD, of Institute Gustave Roussy
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists
Sandip P. Patel, MD
Alissa J. Cooper, MD
Related Content
Danny Nguyen, MD
September 11th 2024

Amivantamab Plus Lazertinib Delays Symptomatic Progression in EGFR+ Advanced NSCLC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Luis Raez, MD, of Memorial Cancer Institute
September 11th 2024

Timing of Immunotherapy Administration Is a Key Question to be Answered in Lung Cancer

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

John V. Heymach, MD, PhD
September 10th 2024

Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC

Hidehito Horinouchi, MD, PhD, medical oncologist, Department of Thoracic Oncology, National Cancer Center Hospital
September 10th 2024

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC